215 First Street
About Constellation Pharmaceuticals
35 articles with Constellation Pharmaceuticals
Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH
Constellation Pharmaceuticals, Inc. announced that the Company will present updates of clinical data from the MANIFEST clinical trial of CPI-0610 in oral and poster presentations at the American Society of Hematology (ASH) annual meeting on December 9.
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two abstracts relating to the MANIFEST clinical trial of CPI-0610 for myelofibrosis – one in association with the American Society for Clinical Oncology (ASCO) annual meeting and the other in association with the European Hematology Association (EHA) annual meeting – published online.
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced an update of the ProSTAR study, its ongoing Phase 1b/2 clinical trial of CPI-1205 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Company raises an aggregate of $160 million in crossover financing in April and initial public offering (IPO) in July
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
Proceeds Will Help to Advance the Company's Cancer Epigenetics Platform and Accelerate Development of Ongoing Therapeutic Programs
Constellation Pharmaceuticals closed on a financing round worth $100 million. The company plans to use the funds to advance several clinical trials.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the Oppenheimer & Co. Inc. 28th Annual Healthcare Conference on March 21 at 3:20 p.m. EDT in the Track 3 room.
Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs
Constellation Pharmaceuticals today announced scientific and clinical presentations on its most advanced EZH2 and BET clinical development candidates at three upcoming conferences.
Constellation Pharmaceuticals Announces Initiation of Phase Ib/II Study of CPI-1205 in Combination with Checkpoint Inhibitors
Constellation Pharmaceuticals announced it has initiated a Phase 1b/2 clinical trial to evaluate CPI-1205, a small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2).
Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer
CPI-1205 is a potent, highly selective, first-generation small-molecule inhibitor of EZH2, a clinically-validated target in cancer.
Constellation Pharmaceuticals today announced it has appointed Emma Reeve as chief financial officer and Brad Prosek as senior vice president, corporate development.
Constellation Pharma Appoints Adrian Senderowicz, M.D., As Senior Vice President And Chief Medical Officer
Constellation Pharmaceuticals Initiates Clinical Development Of CPI-1205, A Novel Inhibitor Of EZH2, In Patients With Lymphoma
Constellation Pharmaceuticals and the University of Pittsburgh School of Medicine Receive Cystic Fibrosis Foundation Research Grant